Drug intelligence / Profile preview

CS24123

Development stage: Preclinical
Lead developer: Akeso
Modality: Small Molecules

Overview

CS24123 is a small molecule inhibitor of ubiquitin-specific-processing protease 1 (USP1) being developed by Chipscreen Biosciences. USP1 is a deubiquitinating enzyme that plays a critical role in the DNA damage response, particularly in the Fanconi anemia pathway and translesion synthesis. By inhibiting USP1, CS24123 prevents the deubiquitination of key substrates like FANCD2 and PCNA, leading to genomic instability and cell death in cancer cells, especially those with homologous recombination deficiencies. The drug is currently in the IND-enabling phase for the treatment of solid tumors.

Targets

USP1 (Ubiquitin-specific protease 1)

Beyond the preview

Go deeper on CS24123.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CS24123.

Explore the full profile